Deckers Brands vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Goleta CA performance footwear (NYSE: DECK) ~$4.9B FY2025 revenue; HOKA $2.2B (+16%), UGG $2.3B Gen Z resurgence, 45%+ DTC mix, competing with Nike, On Running and Skechers.
About
Deckers Brands is a Goleta, California-based footwear and apparel company — publicly traded on the New York Stock Exchange (NYSE: DECK) as an S&P 500 Consumer Discretionary component — designing, marketing, and distributing footwear through four brands: HOKA (performance athletic running and trail shoes), UGG (sheepskin boots, slippers, and casual footwear), Teva (sport sandals), and Koolaburra (accessible sheepskin-style footwear) through approximately 4,300 employees globally. In fiscal year 2025 (ending March 2025), Deckers reported revenues of approximately $4.9 billion with HOKA generating over $2.2 billion (+16% growth) representing the most successful performance footwear brand launch in recent industry history — and UGG generating approximately $2.3 billion in its strongest year yet driven by the sheepskin boot cultural resurgence among Gen Z consumers embracing comfort-forward casual fashion. CEO Dave Powers has executed a brand portfolio strategy that counterintuitively benefits from multi-brand diversity: when outdoor athletic trends favor performance running (HOKA gains), casual comfort trends favor UGG, with the two largest brands often running on different consumer cycle timing. The direct-to-consumer expansion (DTC revenue growing to 45%+ of total sales) captures higher margins than wholesale channel sales — an UGG boot sold through deckers.com or an owned retail store generates 3-4x the gross margin dollar versus the same boot sold through Nordstrom or Dick's Sporting Goods, funding brand investment and driving customer lifetime value through owned digital relationships.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.